Disease activity and treatment in patients with juvenile idiopathic arthritis before transfer to adult care: the first survey in China

中国首次调查幼年特发性关节炎患者转入成人医疗机构前的疾病活动度和治疗情况

阅读:1

Abstract

OBJECTIVES: To analyze disease activity and treatment in patients with juvenile idiopathic arthritis (JIA) before transfer to adult care. METHODS: We retrospectively collected the clinical data of 230 JIA patients (range 14-18 years) in our center from January 2013 to December 2022. We evaluated the clinical features, disease activity, and medication use across various JIA subtypes. RESULTS: 230 patients with JIA were included, and 144 (63%) were male. The distribution of JIA subtypes was dominated by enthesitis-related arthritis (32%), polyarthritis (31%), systemic JIA (27%), and oligoarthritis (10%). Disease activity assessment showed that 87 JIA (38%) were in active disease; while 143 JIA (62%) were in inactive disease, of which 59 patients achieved clinical remission on medicine and 13 patients achieved clinical remission off medicine. Conventional synthetic disease-modifying anti-rheumatic drugs were used in 83% of JIA patients, and biologics in 56%. Clinical characteristics and medication use differed between different subtypes of JIA. The oligoarthritis group had earlier disease onset (P = 0.020) and longer disease duration (P = 0.009) compared to other subtypes. Patients in the RF-positive polyarthritis group had a significantly lower rate of disease inactivity (39%, P = 0.004) than the other subtypes, and a relatively lower proportion of patients achieved clinical remission on medication or discontinuation of medication (18%, P = 0.024). CONCLUSIONS: Some JIA patients were still in active disease before transfer to adult clinics, failing to achieve clinical remission and discontinuation of medication, and required continued treatment. Patients in the RF-positive polyarthritis group were less likely to achieve clinical remission.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。